retatrutide glucagon receptor agonist Retatrutide, a GIP, GLP-1 and agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA retatrutide glp-1 gip glucagon receptor

If Phase 3 data hold up, it becomes less about modality disruption and more about competitive differentiation inside the SM class

A new study led by investigators at Mass General Brigham finds that adding novel weight loss GLP-1 drugs semaglutide and tirzepatide to usual care represents a cost-effective treatment strategy for people with knee osteoarthritis and obesity, with tirzepatide providing greater health benefits at lower cost compared to semaglutide.

While both drugs showed significant weight loss benefits, Zepbound's results were more promising

Our findings offer the structural basis of ago-allosterism at GLP-1R and new knowledge to design better therapeutics

Stay informed and make empowered decisions!

You can get to a more healthy state, which is everyones goal, I think says Ricks.